Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine glucagon is a **29-amino-acid peptide hormone** preparation derived from or corresponding to the porcine form of glucagon, historically used as an **antihypoglycemic agent** and **gastrointestinal motility inhibitor**. It acts as an **agonist of the glucagon receptor**, primarily on hepatocytes, activating adenylate cyclase and increasing intracellular cAMP, which promotes **glycogenolysis** and **gluconeogenesis** and thereby raises blood glucose. Clinically, glucagon products have been used for the emergency treatment of severe hypoglycemia and as a diagnostic aid during radiologic examinations to transiently inhibit GI motility. For the exact entity requested here, the qualifier indicates the **porcine peptide form**, which is biologically very similar to human glucagon but should be treated as a distinct specified peptide source/form rather than collapsed into generic glucagon.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucagon (porcine).